Two years post affordable medicines facility for malaria program: availability and prices of anti-malarial drugs in central Ghana

Background The Affordable Medicines Facility for malaria (AMFm) Program was a subsidy aimed at artemisinin-based combination therapies (ACTs) in order to increase availability, affordability, and market share of ACTs in 8 malaria endemic countries in Africa. The WHO supervised the manufacture of the...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander Freeman (Author), Anthony Kwarteng (Author), Lawrence Gyabaa Febir (Author), Seeba Amenga-Etego (Author), Seth Owusu-Agyei (Author), Kwaku Poku Asante (Author)
Format: Book
Published: Taylor & Francis Group, 2017-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_2cfbc606d7af4c78b74cd24a6562003c
042 |a dc 
100 1 0 |a Alexander Freeman  |e author 
700 1 0 |a Anthony Kwarteng  |e author 
700 1 0 |a Lawrence Gyabaa Febir  |e author 
700 1 0 |a Seeba Amenga-Etego  |e author 
700 1 0 |a Seth Owusu-Agyei  |e author 
700 1 0 |a Kwaku Poku Asante  |e author 
245 0 0 |a Two years post affordable medicines facility for malaria program: availability and prices of anti-malarial drugs in central Ghana 
260 |b Taylor & Francis Group,   |c 2017-12-01T00:00:00Z. 
500 |a 2052-3211 
500 |a 10.1186/s40545-017-0103-0 
520 |a Background The Affordable Medicines Facility for malaria (AMFm) Program was a subsidy aimed at artemisinin-based combination therapies (ACTs) in order to increase availability, affordability, and market share of ACTs in 8 malaria endemic countries in Africa. The WHO supervised the manufacture of the subsidized products, named them Quality Assured ACTs (QAACT) and printed a Green Leaf Logo on all QAACT packages. Ghana began to receive the subsidized QAACTs in 2010. Methods A cross-sectional stock survey was conducted at 63 licensed chemical shops (LCS) and private pharmacies in two districts of the Brong-Ahafo region of Ghana to determine the availability and price of all anti-malarial treatments. Drug outlets were visited over a 3-weeks period in October and November of 2014, about 2 years after the end of AMFm program. Results At least one QAACT was available in 88.9% (95% CI 80.9% - 96.8%) of all drug outlets with no difference between urban and rural locations. Non-Assured ACTs (NAACT) were significantly more available in urban drug outlets [75.0% availability (95% CI 59.1% - 90.9%)] than in rural drug outlets [16.1% availability (95% CI 2.4% - 29.9%)]. The top selling product was Artemether Lumefantrine with the Green Leaf Logo, a QAACT. There was a significant difference in the mean price of a QAACT [$1.04 USD (95% CI $0.98 - $1.11)], and the mean price of a NAACT in both the urban and rural areas [$2.46 USD (95% CI $2.11 - $2.81)]. There was no significant difference in the price of any product that was available in urban and rural settings Conclusion About 2 years after the AMFm program, subsidized QAACTs in Ghana were widely available and more affordable than NAACTs in the Kintampo North District and Kintampo South Municipality of Ghana. The AMFm program appeared to have mostly succeeded in making QAACTs available and affordable. 
546 |a EN 
690 |a malaria 
690 |a artemisinin-based combination therapy 
690 |a subsidy 
690 |a ghana 
690 |a kintampo 
690 |a amfm 
690 |a global fund 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Journal of Pharmaceutical Policy and Practice, Vol 10, Iss 1 (2017) 
787 0 |n http://dx.doi.org/10.1186/s40545-017-0103-0 
787 0 |n https://doaj.org/toc/2052-3211 
856 4 1 |u https://doaj.org/article/2cfbc606d7af4c78b74cd24a6562003c  |z Connect to this object online.